Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Alabama at Birmingham

Sites in Birmingham, AL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1238
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Alabama at Birmingham, Birmingham, AL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Alabama at Birmingham, Birmingham, AL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 109–120 of 1,238 matching trials with a site at University of Alabama at Birmingham, Birmingham, AL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Not yet recruiting Not applicable Interventional

The Effect of Lateral Extra-Articular Tenodesis on Lower-Extremity Lean Mass Recovery Following Anterior Cruciate Ligament Reconstruction

NCT07777458
Site status not listed — check the official record
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction (ACLR)
Interventions
Bone-patellar Tendon-bone (BTB), Bone-patellar Tendon-bone (BTB) and Lateral Extra-Articular Tenodesis (LET)
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

NCT06239116
Site status not listed — check the official record
View directory record Official record
Conditions
Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Interventions
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT
Not yet recruiting Not applicable Interventional

A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

NCT06458907
Site status not listed — check the official record
View directory record Official record
Conditions
Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure, Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency
Interventions
TricValve System, Optimal medical therapy
Device · Drug
Lead sponsor
P+F Products + Features USA Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670
Status at this site: Recruiting
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ITU512, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
9
States / cities
Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT
Active, not recruiting Phase 1 Interventional

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

NCT07333261
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BMS-986453
Drug
Lead sponsor
Susan Bal
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT
Recruiting Not applicable Interventional

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

NCT06911632
Status at this site: Recruiting
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Interventions
ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator
Device · Procedure
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT
Recruiting No phase listed Observational

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

NCT02474160
Status at this site: Suspended
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
National Cancer Institute LAO
Other
Eligibility
2 Months and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
139
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Arroyo Grande, California + 94 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Light Intervention on Recovery in Individuals With Opioid Use Disorder (OUD)

NCT06832007
Status at this site: Recruiting
View directory record Official record
Conditions
Opioid Use Disorder, Sleep, Circadian Rhythms, fMRI Research
Interventions
AYO light glasses (experimental), AYO light glasses (comparator)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257
Site status not listed — check the official record
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT
Recruiting Not applicable Interventional

Diagnosing Epilepsy To EffeCT Change

NCT07110337
Status at this site: Recruiting
View directory record Official record
Conditions
Epilepsy, Epilepsy (Treatment Refractory)
Interventions
Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)
Device
Lead sponsor
Epiminder America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565
Site status not listed — check the official record
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
62
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT
Recruiting Phase 1 Interventional

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT07441694
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
INCA036978, Standard disease-directed therapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
23
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:44 PM EDT

About this University of Alabama at Birmingham institution page

What this page lists
ClinicalTrials.gov records that list University of Alabama at Birmingham in Birmingham, AL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.